Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403447 | 1.00 | NR1H4 (0.65) | NR1H4TDP1 | |
| SCHEMBL25350637 | 0.91 | NR1H4 (0.58) | NR1H4TDP1 | |
| SCHEMBL29406380 | 0.89 | NR1H4 (0.67) | NR1H4TDP1 | |
| SCHEMBL18664593 | 0.89 | NR1H4 (0.67) | NR1H4TDP1 | |
| SCHEMBL30492216 | 0.89 | NR1H4 (0.73) | NR1H4TDP1 | |
| SCHEMBL20518753 | 0.89 | NR1H4 (0.73) | NR1H4TDP1 | |
| SCHEMBL20478980 | 0.88 | NR1H4 (0.62) | NR1H4TDP1 | |
| SCHEMBL25990304 | 0.88 | NR1H4 (0.61) | NR1H4TDP1 | |
| SCHEMBL18664543 | 0.88 | NR1H4 (0.61) | NR1H4TDP1 | |
| SCHEMBL18664858 | 0.87 | NR1H4 (0.67) | NR1H4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350165-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20180282263-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2018-10-04 | — | — | US | disclosed |
| WO-2017049173-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TDP1 3839/4885 |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TDP1 3839/4885 |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TDP1 3839/4885 |
| US-20180282263-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TDP1 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.